Clinical Trial Update: A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2a study evaluating weekly doses of GCS-100 in chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• GCS-100

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED